Treatment of 22Rv1 and Du145 prostate carcinoma cell lines with either one of three previously published DKC1 siRNAs (Montanaro et al, 2006) for 3 days diminished DKC1 mRNA levels by 90–95% compared with cells treated with a control siRNA. This evidence concerns the gene DKC1 and prostate carcinoma.